Table 3.
Logistic regression: Effect of treatment on pCR vs. Non-pCR.
| Variable | Category | UVA | MVA | ||
|---|---|---|---|---|---|
| OR (95% CI) | p-Value | OR (95% CI) | p-Value | ||
| Treatment | NA-CRT | Reference | Reference | ||
| NA-CT | 15.8 (2.58, 96.9) | 0.003 | 24.7 (2.88,211.2) | 0.003 | |
| NA-XRT | 5.73 (1.51, 21.8) | 0.010 | 7.95 (1.87, 33.7) | 0.005 | |
| Age in years | One year increased | 0.99 (0.96, 1.03) | 0.678 | ||
| Sex | Female | Reference | |||
| Male | 0.89 (0.35, 2.28) | 0.816 | |||
| Race/ethnicity | Non-Hispanic White | Reference | |||
| Non-Hispanic Black | 0.74 (0.18, 3.06) | 0.673 | |||
| Hispanic | 1.23 (0.43, 3.51) | 0.701 | |||
| Asian/Unknown | 0.51 (0.03, 8.80) | 0.643 | |||
| Histology | Leiomyosarcoma | 2.05 (0.27, 15.8) | 0.491 | ||
| Myxoid cell/round cell liposarcoma | 0.78 (0.12, 5.13) | 0.799 | |||
| Synovial cell sarcoma | 3.92 (0.59, 25.9) | 0.156 | |||
| Spindle cell sarcoma | 0.31 (0.05, 1.84) | 0.197 | |||
| Dedifferentiated liposarcoma | 1.01 (0.17, 5.96) | 0.994 | |||
| Location | Lower extremity | Reference | |||
| Upper extremity | 1.07 (0.30, 3.80) | 0.920 | |||
| Pre-treatment tumor size in | <5 | Reference | |||
| cm | 5–10 | 0.31 (0.04, 2.14) | 0.234 | ||
| >10 | 0.24 (0.03, 1.66) | 0.148 | |||
| Post-treatment tumor size | <5 | Reference | |||
| in cm | 5–10 | 1.64 (0.45, 5.97) | 0.454 | ||
| >10 | 1.65 (0.44, 6.15) | 0.455 | |||
| Unknown | 1.78 (0.16, 19.37) | 0.635 | |||
| Grade | 2 | Reference | Reference | ||
| 3 | 0.23 (0.06, 0.80) | 0.022 | 0.16 (0.04, 0.7) | 0.015 | |
| Clinical T stage | 1 | Reference | |||
| 2 | 0.36 (0.05, 2.57) | 0.309 | |||
| 3 | 0.24 (0.03, 1.84) | 0.169 | |||
| 4 | 0.29 (0.04, 2.30) | 0.239 | |||
| x | 0.72 (0.00, 137.1) | 0.901 | |||
| Clinical N stage | 0 | Reference | |||
| 1 | 2.62 (0.06, 111.4) | 0.614 | |||
| x | 1.65 (0.02, 164.9) | 0.831 | |||
NA-CT: Neoadjuvant chemotherapy; NA-CRT: Neoadjuvant chemoradiation; NA-XRT: Neoadjuvant radiation; NA: Not applicable. NE: Not estimable.